















The Thesis Committee for Allison Mooney Griffith 
Certifies that this is the approved version of the following thesis: 
 
 
Identifying Functions of Down Syndrome-Related Genes Using  




















Identifying Functions of Down Syndrome-Related Genes Using  








Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Master of Arts 
 






I would first like to thank my professor Jon Pierce-Shimomura for his help and 
support during my time in his lab.  Thank you also to Edward Marcotte for serving on my 
graduation committee and taking the time to read my thesis.  I would also like to thank 
the members of the Pierce-Shimomura lab for their help with this project.  Thank you to 
Kriston McGary for his help compiling our list of HSA21 gene equivalents.  Thank you 
to Sammie Truong for her invaluable help organizing and administering the aldicarb 
assay.  Thank you also to Ashley Crisp, Andrés Vidal-Gadea and Layla Young for their 
help with editing this and other papers.  Finally, I would like to thank my husband and 
family for supporting me through the time I was working on this project.  This project 
















Identifying Functions of Down Syndrome-Related Genes Using  





Allison Mooney Griffith, M.A. 
The University of Texas at Austin, 2010 
 
Supervisor:  Jon Pierce-Shimomura 
 
Down syndrome is one of the most common genetic disorders, resulting in a range 
of neurological and neuromuscular disabilities.  Although the presence of specific 
disabilities varies among individuals with Down syndrome, all individuals with Down 
syndrome are born with hypotonia (low muscle tone) and over half with congenital heart 
defects.  Later in life, all individuals demonstrate intellectual disabilities to varying 
degrees, while many also develop early-onset Alzheimer’s disease.  While the cause of 
Down syndrome is known to be a triplication of the 21
st
 chromosome, it is unknown how 
this extraneous genetic material causes the development of these phenotypes.  We have 
begun research into the biological basis of these disabilities using the tiny nematode, 
Caenorhabditis elegans as a genetic model.  We used the technique RNA interference 
 vi 
(RNAi), which allows us to study the in vivo function of genes by knocking down their 
expression one at a time in a living, behaving animal.  We have used this technique to 
systematically study the in vivo function for genes involved in Down syndrome.  To this 
end, we identified and knocked down C. elegans genes with sequence similarity to 67% 
of genes on the human 21
st
 chromosome genes.  We used these RNAi-treated worms to 
investigate the neuromuscular function of human chromosome 21 gene equivalents by 
assaying locomotion and pharyngeal pumping in a blinded screen.  We used locomotion 
as a measure of neurological and neuromuscular function, while we used pharyngeal 
pumping as a model for cardiac function.  We also performed an aldicarb screen to 
examine the role of some of these genes in the function of the synapse.  Our experiments 
have provided valuable insight into the in vivo function of the vast majority of genes on 
the human 21
st
 chromosome.  This will be vital to identify genes that are potentially 
involved in eliciting Down syndrome-related phenotypes, laying the groundwork for 
further studies into the neurobiology of Down syndrome. 
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Chapter 1: Introduction 
Down syndrome (DS) is the most common genetic cause of intellectual disability, 
occurring at a rate of 1 in ~700 live births in the United States (Canfield et al., 2006). 
 People with DS experience a wide variety of neurological and neuromuscular symptoms 
in addition to varying degrees of intellectual disability and learning and memory 
problems (Korenberg et al. 1994).  For example, DS is the leading known cause of 
neonatal heart defects, leading to a high infant mortality rate without surgical intervention 
(Korenberg et al. 1994; Vis et al. 2009).  Another common symptom of DS, muscle 
weakness (hypotonia), causes problems with both gross and fine motor skills, which leads 
those affected to have trouble speaking, writing, and walking (Pitetti et al. 1992). 
 Furthermore, nearly everyone with DS develops Alzheimer’s-like dementia once they 
reach middle age (Coyle et al. 1988).  By studying the genetic origin of these common 
neurological and neuromuscular phenotypes, we may be able to develop treatments or 
therapies to help improve the quality of life for people with DS. 
While the direct causes of these phenotypes are unknown, the biology of DS has 
been studied to an extent.  For example, we have had evidence for over 50 years that DS 
is caused by trisomy 21, the triplication of the human somatic autosome 21 (HSA21) 
(Jacobs et al. 1959).  However, the mechanisms by which HSA21 causes the DS-
associated phenotypes are unknown.  One of the first models explaining the link between 
DS and trisomy 21 suggested that the burden of the extra genetic material put strain on 
cellular processes on the DS patient, causing the manifestation of all DS symptoms 




that the amount of extraneous genetic material does not account for all the symptoms 
associated with DS (Korenberg et al. 1994; Lyle et al. 2009).  A more recent theory 
suggests that a group of about 30 HSA21 genes, known collectively as the Down 
Syndrome Critical Region (DSCR), are responsible for all DS-associated phenotypes 
(Rahmani et al. 1989).  A mouse model with trisomy of DSCR-homolog genes has been 
developed (Ts1Rhr) (Olson et al. 2004).  Observations of these mice have accounted for 
only some phenotypes, suggesting that the DSCR is not solely responsible for the whole 
complement of DS-associated phenotypes (Belichenko et al. 2009; Olson et al. 2004).  A 
new mouse model of DS, trisomic for over 75% of all HSA21 orthologs, exhibits more 
DS-type phenotypes than the Ts1Rhr model (Yu et al. 2010).  This led to the current 
theory that each DS phenotype is caused by a single, separate gene or small group of 
genes on HSA21 (Lyle et al. 2009).   In other words, the heart defects may be caused by a 
single gene or group of genes, while hypotonia may be caused by a second gene or group 
of genes, and so on.   
Few single genes have been tested for specific genotype-phenotype correlations.  
For example, overexpression of the Drosophila homolog of SYNJ, a HSA21 gene, was 
shown to result in synaptic signaling and locomotion abnormalities in flies (Chang and 
Min 2009).  Furthermore, a study of another HSA21 gene, Dyrk1A, has shown that 
overexpression in mouse models results in DS-like gene splicing errors in neurons 
(Toiber et al. 2010).   
To identify candidate genes that contribute to specific defects, it would be useful 




cardiac function will be more likely to be caused by genes that normally function in the 
heart, while specific neurological defects will be more likely to be caused by genes that 
function in the nervous system.  While the list of protein coding genes on HSA21 has 
been compiled through the human genome project, a comprehensive list of the in vivo 
functions of these genes is mostly incomplete.  Our project begins to fill this critical gap 
in knowledge by studying the function of HSA21 gene equivalents in a genetically 
tractable organism, the tiny nematode Caneorhabditis elegans. 
Unfortunately, human studies into the genetic causes of DS-related phenotypes 
are minimal, with most research focused on case studies and basic observations of the 
physiology of people with DS.  However, work studying people with partial trisomy 21 
has described several ‘susceptibility regions’ on HSA21 that are correlated with various 
DS-associated phenotypes (Lyle et al. 2009).  The incidence of partial trisomy 21 in 
humans is exceptionally low, causing these studies to progress slowly and existing data to 
be plagued by low sample numbers and inconsistent phenotypic observations, making 
statistical analyses questionable. 
 About half of the genes on HSA21 are completely unstudied, making it 
impossible to know if they have a function in the generation of DS-related phenotypes.  
With the exception of the few studies mentioned above, almost all research into the 
biological basis of DS has been performed in mouse models, focusing on the gross effects 
of large groups of genes (Patterson 2009).  Ultimately, an overexpression study will be 




impractical to begin such a study without knowing the function of each gene we propose 
to study. 
The goals of this project are two-fold.  First, we will begin to determine the 
general in vivo function of all HSA21 genes by studying their evolutionarily conserved 
equivalents in C. elegans.  Secondly, we plan to identify those genes which are involved 
in the function of the synapse. This knowledge will allow us to predict which genes likely 
contribute the neurological and neuromuscular phenotypes associated with DS. 
C. elegans is an exceptional model for genetic studies.  It is a well-established 
genetic model for human disease, exhibiting sequence similarity with at least 42% of 
human disease-causing genes (Culetto and Sattelle 2000).  Worms are easy to raise and 
grow quickly, allowing large-scale studies to be performed with minimal investments of 
time and money (Timmons et al. 2001).   
To identify the function of HSA21 gene equivalents in C. elegans, we used a 
technique that will let us observe in vivo effects of gene knockdown.  RNA interference 
(RNAi) allows us to observe gene-specific knockdown effects in a living, behaving worm 
without requiring the generation of mutant strains (Fire et al. 1998).   Feeding worms 
with bacteria expressing double stranded RNA whose sequence is designed to match that 
of a gene of interest will quickly and easily knock down the expression of that gene in the 
worm (Fire et al. 1998; Timmons et al. 2001).   Large-scale RNAi screens are simple to 





Because the C. elegans nervous system is very compact, with only 302 neurons 
connected by only ~8,000 synapses, we can observe a worm’s locomotion and other 
behaviors to assess neurological function.  With only 120 motor neurons, an abnormality 
in any one neuron will likely manifest as an abnormal gait (Chen et al. 2006).   Specific 
changes in locomotion have been shown to indicate underlying abnormal neural function 
(Pierce-Shimomura et al. 2008).  For example, defects in GABA neurons cause the worm 
to contract abnormally when mechanically stimulated on the head (Cinar et al. 2005).    
In addition to identifying genes involved in locomotion and neuromuscular 
functions, we can examine other pathologies associated with DS.  For example, DS is the 
most common known cause of congenital heart disease.  We can use the worm to model 
this pathology as well.  The pharynx, a muscular feeding organ with physiological and 
molecular similarities to the human heart, is an excellent model for cardiac function 
(Avery and Horvitz 1989; Avery and Shtonda 2003; Haun et al. 1998).  Observations of 
the pharynx pumping and morphology can allow us to identify genes that may be 
involved in the congenital cardiac defects associated with DS.  Therefore, through 
behavioral observation of RNAi-treated worms, we can make inferences about the 
function of HSA21 genes. 
As discussed above, RNAi screening allows us to target single, specific genes, 
reducing the incidence of off-target effects that can occur with the use of mutagens or 
pre-existing mutant C. elegans strains.  The procedure we used (as described in Chapter 
3) is a simple way to examine the effects of many genes in a short period of time.  We 




 First, our RNAi library covers more genes than are available as mutants.  Second, all C. 
elegans mutant strains contain secondary mutations in other genes, which can often cause 
errors when attempting to assign a function to single genes.   RNAi in the worm is a 
simple assay with which to examine the function of HSA21 genes in an unbiased way.  
Third, deletion of about 20% of genes in C. elegans produces lethality, making it 
inconvenient to study their in vivo function.  By contrast, RNAi techniques allow us to 
study the function of these critical genes by knocking down their expression levels after 
embryonic development, or by knocking down expression to sub-lethal levels.  
Functional synapses are vital for proper neurological and neuromuscular function.  To 
identify genes that may be involved in the function of the synapse we used an aldicarb 
sensitivity assay (Brenner, 1974).  Aldicarb is an acetylcholinesterase inhibitor which 
induces paralysis in worms by increasing the concentration of acetylcholine at the 
neuromuscular synapses.  By observing RNAi-treated worms’ responses to aldicarb, we 




Chapter 2: Generation of list of HSA21 gene equivalents in C. elegans 
Purpose 
To ensure that we focused on genes relevant to DS, identification of C. elegans 
gene equivalents of HSA21 genes was necessary before beginning our screen.  We chose 
to examine the protein-coding genes of HSA21 because it is likely that the phenotypes 
associated with DS are due to an over-expression of these genes.  People with DS exhibit 
abnormally high concentrations of proteins encoded by the 21
st
 chromosome, often 1.5 
times higher than normal (Lockstone et al. 2007).  The relatively small number of 
protein-coding genes (226) on HSA21 makes this a project that could be completed in a 
reasonable period of time.   Like humans, C. elegans has over 20,000 genes.  More than 
half of these genes have sequence similarity to human genes (C. elegans Sequencing 
Consortium, 1998).  Therefore, it was likely that we would find many gene equivalents 
between HSA21 genes and C. elegans. 
Methods 
We began by collecting sequences of HSA21 protein-coding genes predicted by 
the manually curated Vertebrate Genome Annotation genome database (VEGA, July 
2009, Wilming et al. 2007).  VEGA identified 226 genes on HSA21 as protein-coding 
through sequence analysis.  We then used these gene sequences to BlastP against the  
C. elegans genome (Wormbase Release WS203).  Worm genes showing good sequence 
similarity (e value>1E-4) were considered orthologs.  The remaining genes were then 
searched for paralog relationships to C. elegans genes (O’Brien et al. 2005).  Paralogs are 




functionally similar (O’Brien et al. 2005).  Together, we will call the orthologs and 
paralogs ‘gene equivalents.’ 
Results 
Two general groups of human genes were identified, those with C. elegans gene 
equivalents and those without (Figure 1).  The majority of the human protein-coding 
genes (154) were represented by 192 C. elegans genes.  This means that 67% of HSA21 
genes are represented in the worm.  Most of these genes (119) were found to have 
orthologs in the C. elegans genome, while a few were identified as paralogs (35). 
The remainder of the HSA21 genes (72) are unrepresented in the C. elegans 
genome.  A large expansion of keratin genes accounts for 46 of the genes on HSA21. 
 Keratin is involved in human hair and skin growth, and thus is not present in C. elegans. 
 Interestingly, people with DS often have atypical hair and skin morphology.  For 
example, alopecia (baldness) is common in this population (Korenberg 1994).  Although 
keratin is over-expressed in people with DS, it is unlikely that it is involved in 
neurological disabilities associated with the disease.  
Beside the keratin genes on HSA21, an additional set of 26 genes had no 
equivalent C. elegans gene (‘Unique Genes’ in Figure 1).  These genes all have 
vertebrate- or mammalian-specific functions, and therefore are not present in the C. 
elegans genome.  For example, the genes IFNGR2 and MX1 are involved in vertebrate-
specific immune functions.  One gene in this group which may have a role in 
neurological function is OLIG1.  It is involved in the function of oligodendrocytes, which 




2006, Wu et al. 2006).  It is possible that myelination could be involved in the abnormal 
neurological function of people with DS.  However, the invertebrate C. elegans does not 
have myelin, and no OLIG1 gene equivalent is present in the worm genome. 
Discussion 
Based on the sequence similarities between human and C. elegans genes, we 
conclude that there is sufficient genetic identity to warrant the use of C. elegans as a 
model to study the function of HSA21 genes.  A significant portion of HSA21 has 
sequence similarity to the C. elegans genes (67% of all HSA21 genes are represented in 
the C. elegans genome, 85% when keratin genes are excluded).  This means that most of 
the genes involved in the neurological and neuromuscular abnormalities associated with 





Chapter 3: Primary RNAi screen of HSA21 equivalents 
Purpose  
  Even though DS is a disease of overexpression, simple techniques to knock down 
gene expression can reveal a lot about the genetic origin for DS-associated 
phenotypes.  RNA interference (RNAi) has proven its usefulness as a method of studying 
gene function and human diseases including Alzheimer’s disease, metabolic syndrome 
and cancer (reviewed by Wolters and MacKeigan 2008).  RNAi can easily be applied to 
C. elegans to quickly observe the effects of gene knockdown in a living, behaving 
animal.  By feeding worms bacteria expressing RNA with sequence similarity to the gene 
equivalents of HSA21, we can quickly and easily observe the in vivo effects of post-
embryonic down-regulation of any target genes (Timmons et al. 2001).  This allows us to 
make conclusions regarding the function of these genes.  This information can be 
extrapolated to humans and may lead to inferences about the genes’ contributions to the 
phenotypes of people with DS.    
Methods 
Generation of RNA-expressing bacterial strains.  We obtained 192 RNA-
expressing bacterial strains (listed in Appendix) from Geneservice (Nottingham, UK) that 
correspond to genes on HSA21.  Most of the strains were publically available.  An 
additional 33 strains were custom ordered through Geneservice specifically for this 
project and have not been studied previously.  However, 21 (Table 1) of the cultures 
generated by Geneservice were not able to grow.  Because Geneservice was unsuccessful, 




are difficult to successfully generate.  Nonetheless, it is important that we examine as 
many genes as possible, so we attempted to generate these strains ourselves. 
We started by examining the gene sequences as they are curated on Wormbase 
(Release WS203) and designing primers to cover approximately 300-500 bp of gene exon 
sequence.  Using a standard restriction digest and ligation cloning protocol (Fraser et al. 
2000), we inserted the gene sequence into L4440 plasmids.  This plasmid was used to 
generate the RNAi by feeding strains in both the original study (Timmons et al. 2001) 
and in the RNAi library obtained from Geneservice (Nottingham, UK).  Appropriate 
insertion was confirmed by PCR.  Correctly cloned plasmids were transformed into 
HT115 strain of E. coli, again following the established protocol for generation of RNA-
expressing bacterial strains for RNAi in C. elegans (Fraser et al. 2000). 
RNA interference.  Our RNAi library, compiled by Geneservice (Nottingham, 
UK), consisted of E. coli (strain HT115) transformed with a small portion of an HSA21 
gene equivalent cloned into L4440 plasmid, as described above.  Neurons in C. elegans 
are known to be resistant to RNAi treatment by feeding (Timmons et al., 2001). 
 Therefore, we used a neuronal RNAi-sensitive C. elegans strain, nre-1(hd20);lin-
15b(hd126) (BZ1272), because we were most interested in the neuronal and 
neuromuscular effects of RNAi treatment (Schmitz et al. 2007).   
The procedure for RNA-interference is straightforward and takes less than two 
weeks to complete an assay (outlined in Figure 2).  Because minimal active time is 
required, many assays can be run in parallel.  First, RNA-expressing bacteria were 




contamination of liquid cultures).  The next day, ~500 μL of liquid culture was grown on 
standard nematode growth media (NGM) plates including 1mM isopropyl ß-D-1-
thiogalactopyranoside (IPTG) to induce expression of exogenous RNA by the T7 
promoter.  Once a bacterial lawn has sufficiently grown, RNAi-sensitive worms were 
quickly bleached in a 2:1 mixture of bleach and 1 M NaOH to remove any bacteria and 
kill all post-embryonic worms.  A single dead, gravid hermaphrodite containing 
approximately 8 eggs was picked to each plate.  The eggs inside the dead adult were 
allowed to hatch and grow over the next 8 days at room temperature, with observation on 
days 1, 2, 4, 6, and 8.  This time period covers two generations.  The first generation 
experiences purely post-embryonic effects of the RNAi treatment, while the second 
generation also experiences maternal or pre-embryonic effects.  We identified genes that 
elicited general phenotypes when knocked down, and also phenotypes known to be 
involved with neurological and/or neuromuscular functioning, and thus may have an 
important role in the neurological phenotypes of people with DS. 
To examine the effects of the RNAi treatment, we watched for 36 different 
phenotypes as detailed in Table 2.  We were able to observe each phenotype through a 
simple dissecting microscope in minutes, allowing the screening of thousands of worms 
during this procedure.  The phenotypes on our list can be broken down into two general 
groups: those with a morphological basis and those often associated with neurological or 
neuromuscular function.  We consider phenotypes resulting in abnormal locomotion or 
pharyngeal pumping as those with a ‘neurological or neuromuscular basis’.  Because the 




neuron often manifests as a gross phenotype such as abnormal movement.  For example, 
ablation of AVA and AVD neurons prevents the worm from performing reversals in 
response to probing with a wire, while ablation of dopaminergic neurons will prevent the 
worm from performing its usual search pattern when looking for food (reviewed by 
deBono and Maricq 2005).  Phenotypes usually associated with neurological components 
are in bold in Table 2.  
The phenotypes we studied are mostly those in common use throughout the worm 
community, but several were defined specifically for our study.  For example, we defined 
five phenotypes that can be observed after probing the worm on the head with a platinum 
wire.  Usually, a wild-type worm will reverse, propagating 2 to 4 full body bends down 
the length of its body before going forward again.  However, mutant worms will 
sometimes propagate more body bends (Ere), fewer body bends (Pre), move more slowly 
(Sre), contract all its body muscles at once (Shr) or become momentarily paralyzed (Fai).  
We believe it is unlikely that these phenotypes will arise from defects other than those 
with a neurological or neuromuscular basis. 
Results 
Generation of RNA-expressing bacterial strains.  Despite repeated efforts to 
generate the missing bacterial strains, we were unsuccessful.  Because both we and the 
Ahringer group (Cambridge) were unable to generate these clones, we suspect that there 
is something unknown about the genes in question that prevents their successful 




similarity with the L4440 plasmid, causing secondary structures to form between the 
gene insert and the plasmid during the cloning process. 
RNA interference.   More than half of the 170 RNAi treatments tested resulted in 
an observable neuromuscular or neurological phenotype (Figure 3 and Appendix).  Of the 
170 genes tested, 64% showed locomotor phenotypes only, while only 2% of treatments 
elicited exclusively pharyngeal phenotypes.   A large portion of treatments (14%) elicited 
both pharyngeal and locomotor phenotypes simultaneously. 
 Discussion 
 We have assayed the in vivo function of the great majority of HSA21 gene 
orthologs identified in our study.  The number of RNAi treatments eliciting neurological 
phenotypes may seem high upon first glance (80%), but there is evidence that 
approximately two-thirds of all genes are expressed in neurons (Bargmann 1998).  As 
stated previously, any treatment that elicits abnormal locomotion or pharyngeal pumping 
is considered to have a putative neurological function. 
 A more in-depth look at the treatments eliciting neurological effects revealed 
some interesting results.  For example, a large portion of RNAi treatments elicited 
abnormal phenotypes during reversals (Ere, Fai, Pre, Shr, Sre, and Ure).  Some of the 
genes which elicited these phenotypes, such as worm orthologs of DYRK1A (Pre), 
DSCR1 (Pre), and SOD1 (Sre), have not previously been associated with neurological 
phenotypes.  This makes sense because the reversal phenotypes defined for this project 
have never before been studied, and the putative neurological functions of these genes 




gene DYRK1A has been shown to cause developmental brain defects in partially trisomic 
mice (Guedj et al. 2009).   
A second interesting group is the treatments that elicited the shrinking (Shr) 
phenotype.  Shrinking worms contract all muscles when they are tapped on the head with 
a platinum wire, which makes their bodies appear to shrink.  Shrinking suggests these 
genes are involved in GABAergic signaling.  Reduction in GABA signaling due to gene 
knockdown or mutation removes neurochemical inhibition on body muscles.  Thus 
making the worm more likely to contract its body wall muscles simultaneously, leading 
to shrinking of the body.  Seven RNAi treatments were observed to elicit the shrinker 
phenotype, orthologs of STCH, ZNF294, C21orf45, DONSON, HMGN1, PRDM15, and 
TRPM2.  None of these human genes or their C. elegans orthologs have been previously 
implicated in GABA signaling.  Future studies in our lab will investigate whether these 
genes are expressed and/or function specifically in GABAergic neurons. 
 In addition, we identified 27 RNAi treatments which elicit pharyngeal pumping 
and morphological abnormalities.  As stated before, we used the pharynx as a model for 
cardiac function due to its molecular and functional similarities to the human heart.  
Several genes in this group have not previously been identified as being involved in 
pharyngeal function.  Interestingly, orthologs of four genes identified in this screen 
(CLIC6, ABCG1, CRYAA, and PFKL) are located in an HSA21 cardiac function 
susceptibility region (Barlow et al. 2001).  This finding together with the data gathered 




RNAi is a valid method not only to confirm gene function in a neurological and 
neuromuscular context, but also as a method to implicate new genes in these processes. 
 RNAi is an excellent tool for studying functional genetics in C. elegans, but the 
technique does have some drawbacks.  While we try to standardize treatments, RNAi is 
notorious for producing variable results.  For example, an individual worm may eat more 
or less RNA-expressing bacteria than other worms, exposing itself to more or less RNAi.  
This can result in a population of worms with a range of phenotypes, from mild to severe.  
To make sure that we did not discount a gene treatment because the phenotype showed 
low penetrance due to the variability of RNAi treatment, we counted every instance of 
abnormal phenotypes.  As long as a single worm in a population exhibited a phenotype, 
that treatment was scored for that phenotype.  This, while it may increase the number of 
false positives, prevents us from missing genes that may be relevant to the phenotypes of 
DS.  Any false positives we obtained can be identified by further RNAi screening and 





Chapter 4: Screen of synaptic function of HSA21 equivalents using aldicarb 
Purpose 
Synaptic transmission is vital to an organism’s neurological and neuromuscular 
function.  One technique that lends itself well to C. elegans, but is impractical in other 
organisms, is the analysis of synaptic transmission through the use of the 
acetylcholinesterase inhibitor aldicarb (Brenner 1974).  The use of this compound, 
especially in conjunction with an RNAi screen, allows us to quickly identify those gene 
products which function at the synapse using a simple behavioral assay.  The aldicarb-
sensitivity assay is a powerful tool, allowing us to quickly and easily identify synaptic 
functions of the genes of interest.  
The aldicarb sensitivity assay takes advantage of the mechanism that exists at the 
neuromuscular synapse to constrict muscles using the neurotransmitter acetylcholine.  In 
a healthy animal, acetylcholine is released by the presynaptic cholinergic neuron.  As the 
acetylcholine accumulates in the synapse, the postsynaptic muscle is stimulated by 
neurotransmitter and contracts.  The enzyme acetylcholinesterase degrades the 
acetylcholine, clearing it from the synapse and allowing the muscle to relax (Brenner 
1974; Mahoney et al. 2006).  Aldicarb is an acetylcholinesterase inhibitor, preventing 
acetylcholine from being degraded within the synapse.  Exposure to aldicarb causes 
acetylcholine build-up in at the synapse, paralyzing the worms over time due to 
overstimulation and contraction of muscles (Mahoney et al. 2006).  The amount of 
exposure required to cause a worm to become paralyzed can be altered in mutant or 




by RNAi is involved in clearing the acetylcholine or reducing the amount of 
acetylcholine that is initially released into the synapse, the worm will become paralyzed 
more quickly when exposed to aldicarb (hypersensitive, Figure 4a).  Mutations and 
expression knock down of different genes can cause the worm to become resistant to 
aldicarb treatment (Figure 4b).  Key genes that are involved in the packaging and release 
of acetylcholine at the synapse have been identified through aldicarb screens (Brenner 
1974; Mahoney et al. 2006). 
Methods 
Gene selection.  Because the gene selection assay for all 192 HSA21 gene 
equivalents would have taken too long, we selected and assayed 21 genes based on their 
putative neurological or neuromuscular function.  Genes whose RNAi treatments resulted 
in locomotion or pharyngeal pumping anomalies in the worm were chosen first.  We 
further narrowed the list by removing all genes whose expression patterns were not 
reported in the worm, or whose expression pattern did not include neurons, muscles 
and/or pharynx.  Of the genes that met these requirements, 28 genes were selected to be 
studied in the following procedure (Table 3).   
RNAi.  Prior to undergoing the aldicarb sensitivity assay, worms were fed with 
RNA-expressing bacteria, as described in the previous chapter.  The RNA-expressing 
bacteria was grown in liquid culture and seeded onto IPTG-containing NGM plates.  
BZ1272 worms were bleached, and a dead, gravid adult was placed on each dry, seeded 
plate.  The worms were allowed to grow on the RNA-expressing bacteria for 8 days 




 Aldicarb sensitivity assay.  This assay is based on the procedure published in 2006 
by Mahoney et al., that standardized the use of aldicarb sensitivity assays in C. elegans.  
After 8 days of feeding on the RNA-expressing bacteria, worms were picked to unseeded 
plates containing 0.5 mM aldicarb in NGM.  Whenever possible, 25-30 young adult 
worms were assayed from each treatment.  RNAi treatments can have many effects, 
including deficits in viability and offspring production.  In these cases, we picked as 
many adult worms as had survived.  All worms were observed at the start of the assay 
(time=0) to ensure that they were not dead or paralyzed.  The number of worms moved to 
the aldicarb plate was noted, and the assay began.  Every hour for the following 6 hours, 
the number of paralyzed worms was noted.  Paralysis was defined as a worm showing no 
movement or pharyngeal pumping, spontaneously or after three pokes on the head and 
tail.  After 6 hours, the number of remaining, moving animals was noted.  Aldicarb 
assays on RNAi-treated worms were performed in triplicate and seven times for the 
control condition where animals were fed bacteria with the L4440 plasmid that does not 
produce double-stranded RNA. 
Results 
 In control experiments, mutant strains that had been previously been shown to be 
resistant and hypersensitive to the paralyzing effects of aldicarb responded as expected 
over the 6-hour treatment period in comparison to a wild-type strain (N2) (Mahoney et al. 
2006).  For example, the diacylglycerol kinase theta mutant (dgk-1) was hypersensitive 
because deletion of this gene causes enhanced release of acetylcholine at synapses 




function mutations in the gene result in severely compromised synaptic transmission 
(Figure 4b).  These pilot results indicate that our protocol for the aldicarb assay can 
correctly identify genetic perturbations that up and down-regulate the in vivo function of 
synaptic machinery. 
 For our RNAi aldicarb sensitivity assay, we found that the fraction of animals 
moving decreased over the time as above with aldicarb treatment.  Animals fed bacteria 
containing no double-stranded RNA served as the control.  On average, these control 
animals dropped to 70 % moving after 6 hours treatment (n= 7 assays, Figure 4c).   
To identify which genes may positively or negatively regulate synaptic 
transmission, we compared which RNAi treatments caused animals to become paralyzed, 
on average, faster or slower than control worms.  Due to the variable penetrance of RNAi 
effects, we only considered RNAi treatments that produced average effects above and 
below the standard error of the mean for the control animals.   
Of the 28 genes targeted via RNAi, 7 produced lethality and/or early 
developmental arrest phenotypes which precluded obtaining enough individual animals 
for analysis. For the remaining targeted genes, we found that knockdown of 11 of them 
caused no change from the control group (gray traces in Figure 4c).  Knockdown of 5 
genes caused animals to show resistance to aldicarb relative to control suggesting roles 
for these targeted genes in synaptic function.  These included worm gene equivalents to 
the human genes: ITSN1, BRDWR1, C21orf63, DSCR1, and PIGP/DSCR5.  Knockdown 
of 5 additional genes caused animals to show hypersensitivity to aldicarb relative to 




function.  These included worm gene equivalents to the human genes: TTC3, SFRS15, 
GABPA, ANKRD21/POTE, and NCAM2.   
Discussion 
 The greatest advantage of the aldicarb-sensitivity assay is that it permits the  
assignment of synaptic functionality to specific genes based on a simple behavioral 
screen rather than through extensive electrophysiological analyses.  Those genes 
designated hypersensitive (those which became paralyzed more quickly, and at a higher 
percentage than wild-type) likely function in vivo in removal or prevention of 
acetylcholine entering the synapse.  These worms become paralyzed more quickly than 
wild-type worms due to more rapid buildup of acetylcholine in the synapse.  While some 
of these genes (TTC3 and GABPA) have been studied for their role in neuronal function, 
others including SFRS15 and ANKRF21/POTE have not (Berto et al., 2007; Herndon and 
Fromm, 2008).  Alternatively, genes resulting in aldicarb resistance when knocked down 
are likely involved in the production, packaging or release of acetylcholine into the 
synapse.  Knockdown of these genes reduces the amount of acetylcholine released into 
the synapse, lengthening the amount of aldicarb exposure required to induce paralysis. 
Many of the resistant genes identified here were previously indicated as potentially being 
important in the DS critical region (ITSN1, DSCR1, and PIGP/DSCR5) (Belichenko et 
al., 2009).  However, other genes have not been studied at all in the context of 
neurological dysfunction in DS (BRDWR1 and C21orf63).  Genes identified in our 
aldicarb screen will be studied further with the C. elegans system to investigate their 




Chapter 5: Future directions 
 In the future, we intend to generate bacterial strains expressing double-stranded 
RNA to target the 21 as yet unrepresented genes.  While we were unable to generate 
these strains, there are alternative methods for strain generation.  For example, we would 
like to try to generate these strains using a different plasmid.  L4440 (the plasmid used 
for the existing RNAi strains) lacks a blue/white screening element, making the screening 
of transformed strains difficult and time consuming.  We could obtain or generate a 
plasmid with the same elements as L4440, but which includes a blue/white screen 
element.  Second, we suggest that using different or smaller portions of the genes in 
question could make the generation of clones easier. 
Furthermore, we plan to continue the aldicarb sensitivity assay, increasing the 
numbers of worms tested with each RNAi treatment will help to overcome the inherent 
variability of the procedure.  We also plan on screening the remaining 162 HSA21 genes 
that have been untested to date.  While we attempted to enrich for genes that had a role in 
neurological or neuromuscular function, it is possible or even likely that there are other 
HSA21 genes with functions relevant to DS-associated phenotypes. 
We will also confirm the results of the RNAi screen through the use of available 
worm knock-out strains.  Only a portion of the HSA21 gene equivalents have been 
knocked out in worms, but these can be helpful to determine the true validity of our 
RNAi screen.  We will examine the knock-out worms, watching for the 36 phenotypes 
we used in our RNAi screen and performing aldicarb-sensitivity assays.  This will 




 While knockdown studies can tell us a lot about the function of HSA21 genes, DS 
is a disease of overexpression.  Thus, we also need to examine the neurological and 
neuromuscular affects of overexpression of HSA21 gene equivalents.  To do this, we will 
overexpress HSA21 gene equivalents one at a time or in groups in wild-type worms.  
Single extra copies of genes of interest can easily be introduced into the genome through 
the use of MosSCI single-copy insertion techniques (Frøkjaer-Jensen et al. 2008).  Our 
lab has already begun this work, with promising results (Griffith and Pierce-Shimomura 






Chapter 6: Conclusion 
Our research is a step toward understanding the biology of DS and the 
contribution of HSA21 genes to the phenotypes associated with DS.  While previous 
research has focused on the functions of larger groups of genes (the DS critical region, 
for example), we are the first to use a systematic approach to study the individual in vivo 
functions of such a large set of HSA21 genes in any animal.  Their genetic similarities to 
humans and ease of use as a neurological model make C. elegans a more powerful tool 
for this kind of study than any other model organism.  In addition to mice, for example, 
cell lines have been suggested as a model for DS, but their inherent aneuploidy negates 
any use they might have in studying a disease of gene dosage (Cimini and Degrassi, 
2005).  An alternative approach to control chromosome number would use human 
embryonic stem cells as a model for the effects of trisomy 21, however, this approach has 
its own limitations with in vivo relevance and ethical constraints (Biancotti et al. 2010) 
We have used RNAi in C. elegans to examine the in vivo function of HSA21 gene 
equivalents.  We have determined that 80% of the 170 HSA21 gene orthologs exhibit 
neurological or neuromuscular phenotypes when knocked down.  Also, the aldicarb 
sensitivity assay in conjunction with RNAi has proven to be a particularly powerful tool.  
This assay has identified several genes with novel functions at the synapse. Genes that we 
identified as having neurological function or specific function at the synapse in worms 
are likely to have vital roles in the neurological or neuromuscular function of people with 




DS is a disease of overexpression, not of knockdown.  While we have studied 
only the knockdown of gene expression, we can draw conclusions regarding the function 
of HSA21 genes in the context of overexpression, paving the way for overexpression 
studies.  Often, knockdown of a gene has an opposite effect to that of overexpression 
(Südhof 2008).  Alternatively, in the case of dominant negative effects, knockdown and 
overexpression will elicit the same phenotype (Südhof 2008).  We have made progress in 
understanding the function of these genes.  Knowing the function of HSA21 genes sets 
the stage for further studies of gene overexpression, and ultimately a deeper 




Table 1: 21 Genes unrepresented in the RNAi library.  Twenty-one bacterial strains in 
the RNAi library express RNA with sequence similarity to C. elegans HSA21 gene 
equivalents.  We were unable to generate these clones. 





LIPI R155.1 mboa-6 
AF165138.7 Y77E11A.16  
MRAP C14A4.15 srv-2 
URB1 T05H4.10  
OLIG2 Y105C5B.29 hlh-32 
TMEM50B Y74C10AL.2  
SLC5A3 F52H2.4  
CLIC6 Y105E8A.22 exc-4 
SETD4 Y92H12BR.6 set-29 
WRB Y50D4A.2  
SH3BGR E02A10.2 grl-23 
PCP4 ZK1320.13  
DSCAM Y42H9B.2 rig-4 
AP001631.10 Y49E10.29  
PTTG1IP C37C3.12  
C21orf70 C18H7.3 col-102 
POFUT2 K10G9.3 pad-2 
PCBP3 Y119D3B.17 pes-4 
COL6A1 M199.5 col-135 
MCM3AP JC8.13 tag-115 





Table 2: Phenotypes observed. We screened for 36 different gross phenotypes when 
conducting our RNAi screen.  * Indicates uncommon phenotypic descriptor designed 
specifically for our study.  Phenotypes usually related to neuromuscular and/or 
neurological development and/or function noted in bold.  Other phenotypes were same as 






















Lvl Larval Lethal Shr*  Shrinking 






Slu  Sluggish 
Dpy Dumpy Mlt Molting 
Defects 
Sre*  Slow Reversals 





Emb  Embryonic 
Lethal 
Pmd*  Pharynx 
Morphology 
Defect 
Stp Sterile Progeny 
Ere*  Extended 
Reversals 
Pmp*  Pharynx Pump 
Defect 
Unc  Uncoordinated 
Fai*  Fainter Pre*  Premature 
Reversals 
Unm*  Unmotivated 
Gro Growth 
Defective 














Table 3: Genes selected for screening with the aldicarb sensitivity assay. Thirty genes 
were selected for screening with the aldicarb sensitivity assay.  This list was enriched for 
genes likely involved in neurological or neuromuscular function. * indicates strains that 
did not grow, and were not assayed for aldicarb sensitivity. 





TPTE T07A9.6 daf-18 
ANKRD21  T28D6.4  
RBM11 C08B11.5* sap-49 
NCAM2 F15G9.4 him-4 
NCAM2 ZK377.2 sax-3 
MRPL39 C47D12.6* trs-1 
GABPA T08H4.3 ast-1 
GABPA C42D8.4 ets-5 
GABPA C37F5.1 lin-1 
APP C42D8.8* apl-1 
ADAMTS1 F25H8.3* gon-1 
ADAMTS5 C37C3.6* mig-6 
SFRS15 D1007.7 nrd-1 
HUNK T01C8.1 aak-2 
C21orf63 F32A7.3 eva-1 
ITSN1 Y116A8C.36 itsn-1 
DSCR1 F54E7.7 rcn-1 
CLIC6 F26H11.5 exl-1 
RUNX1 B0414.2 rnt-1 
DOPEY2 Y18D10A.13* pad-1 
PIGP Y48E1B.2  
TTC3 R09E12.3 sti-1 
DYRK1A F49E11.1 mbk-2 
BRWD1 F55B12.3 sel-10 
MX2 C02C6.1 dyn-1 
RIPK4 B0350.2 unc-44 
ABCG1 F19B6.4 wht-5 
TSGA2 T22C1.7 jph-1 






Figure 1: C. elegans equivalents of HSA21 protein coding genes.  The numbers 
represent human genes which show sequence similarity to a C. elegans gene.  Including 
keratin genes, 67% of all HSA21 protein-coding genes are represented in the C. elegans 

























Figure 2: Outline of RNAi procedure. Negative control: HT115 E. coli containing 
L4440: no phenotype.  Positive control: apl-1, phenotypes: sterile, larval arrest.  RNAi 









Figure 3a: Results of RNAi screen. Percentage of total worms displaying neurological or 
neuromuscular phenotypes when treated with RNAi. 
 
 
Figure 3b.  Percentage of worms displaying each phenotype.  An individual worm may 
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Figure 4a.  Hypersensitive mutant example.  Aldicarb hypersensitive (Hic) mutant,  
dgk-1, compared to wild-type in an aldicarb sensitivity assay. 
 
 
Figure 4b.  Resistant mutant example. Aldicarb resistant (Ric) mutant, snt-1, compared 







































Figure 4c.  Plot of average percentage of animals moving per assay over time course 
of aldicarb exposure.  Each assay included 20 or more individuals.  Control worms were 
not subject to gene-specific RNAi treatment (black line).  Error bars represent s. e. m 
RNAi treatments that were not significantly different from control are represented in 
gray, while those that produced significant hypersensitivity or resistance to aldicarb 
treatment are represented in cool or warm colors, respectively. Error bars for these later 
groups do not overlap with those from the control group and are not plotted for clarity.  





Appendix: RNAi screen results.  Check marks indicate publically available mutant 
strains (Red=C. elegans Genetic Center, Minnesota, USA; Blue= National Bioresource 
Project, Japan).  Genes are listed in the order they are arranged on HSA21. Genes without 
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C08B11.5 sap-49 RBM11 
 
1 E-13 Ste Gro Unc, Unr Pmp Dau, Bmd 
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C01G8.9 let-526 BTG3 
 
  Emb 
  
Pmp Pvl, Bmd, Vac 
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F15G9.4 him-4 NCAM2 
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Muv, Pvl, Bmd 
C42D8.8 apl-1 APP √√ 9 E-30 Ste Lva Ure 
 
Bmd 
ZK1010.7 col-97 CYYR1 
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C37C3.6 mig-6 ADAMTS5 √ 6 E-41 Ste 
 
Sre, Unr Pmp Pvl, Rup 
C33C12.9 
 
HEMK2 √ 1 E-38 
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K09C4.8 sul-1 C21orf6 √ 7.3 Emb 
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Pre Pmp Pvl, Vac 












Y51A2D.5 hmit-1.2 CLDN17 
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T01C8.1 aak-2 HUNK √ 8 E-54 
  
Unc, Pre Pmp Egl 
H39E23.1 par-1 HUNK √√ 4 E-52 Emb 
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T20D3.7 vps-26 DSCR3 √ 8 E-11 Ste Gro 
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